Anupam Rasayan India Limited filed a regulatory disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, intimating the stock exchanges about the issuance of a press release containing audited financial results (standalone and consolidated) for the quarter and financial year ended March 31, 2026, approved by the Board of Directors.

Consolidated Financial Highlights for Year Ended March 31, 2026:

  • Total Revenue: ₹23,836 million (up 65% YoY from ₹14,485 million in FY25)
  • EBITDA (including other income): ₹5,430 million (up 32% YoY from ₹4,123 million in FY25)
  • EBITDA Margin: 23% for full year
  • Profit After Tax: ₹2,222 million (compared to ₹1,600 million in FY25)

Consolidated Financial Highlights for Quarter Ended March 31, 2026:

  • Total Revenue: ₹6,392 million (up 26% YoY from ₹5,057 million in Q4FY25)
  • EBITDA (including other income): ₹1,407 million (down 6% YoY from ₹1,500 million in Q4FY25)
  • EBITDA Margin: 22% for Q4FY26
  • Profit After Tax: ₹560 million (compared to ₹629 million in Q4FY25)

Management Commentary

Mr. Anand Desai, Managing Director, commented that FY26 was a landmark year marked by strong operational execution, strategic expansion, and progress toward building a globally integrated specialty chemicals and CDMO platform. The company achieved its highest-ever annual sales and operating cash flow performance, driven by commercialization of new products, addition of new multinational customers, and expanding engagements across key business verticals.

Strategic Developments

  • Successfully acquired Jayhawk Fine Chemicals in the United States, which delivered proforma revenue of US$95 million
  • Signed definitive agreement to acquire Bliss GVS Pharma to strengthen pharmaceutical value chain capabilities
  • The company continues to strengthen presence in niche and complex chemistries with strong entry barriers

Business Overview

Anupam Rasayan India Ltd. is engaged in custom synthesis and manufacturing of specialty chemicals with two verticals: Life science related Specialty Chemicals (Agrochemicals, Personal Care, Pharmaceuticals) and Other Specialty Chemicals (Polymer Additives). The company serves over 185+ domestic and international customers and operates eight manufacturing facilities (six in Gujarat, one in Tamil Nadu, one in U.S.) with aggregate installed capacity of ~200,000+ MT as of March 31, 2026.

Additional Information

The press release will be hosted on the company website at www.anupamrasayan.com. The document includes standard forward-looking statements disclaimer noting that actual results may differ due to economic conditions, tax laws, inflation, litigation, and other factors.